ANIX Anixa Biosciences Inc
Company Analysis
Latest News
🟢 ANIX is trading 5% up today after treating first patient in fifth cohort of CAR-T trial
ANIX is trading at $3.11 (+5.06%) today after treating the first patient in the highest-dose fifth cohort of its Phase 1 ovarian cancer CAR-T trial. • No...
🟢 ANIX is trading 9.5% up today after ovarian cancer CAR-T trial milestone
ANIX is trading 9.5% up today at $3.24 as investors refocus on progress within its ovarian cancer CAR-T program. • The company recently treated the first...
Anixa's Ovarian Cancer Therapy Hits Its Highest Dose Yet — But Can a $110 Million Biotech Sustain the Momentum?
Shares of Anixa Biosciences surged 12.5% to $3.33 after hours on July 8, reversing a classic "sell the news" dip that dragged the stock from $3.27 to $2.96 in...
🟢 ANIX is trading 12.5% up today following positive ovarian cancer CAR-T trial data
ANIX is trading at $3.33 (12.5% up) in after-hours trading following positive clinical updates from its ovarian cancer CAR-T trial. • The trial successfully...
🔴 ANIX is trading 5.6% down today on a sell the news reaction to its ovarian cancer CAR-T trial update
ANIX is trading at $2.88 (-5.57%) following a sell the news reaction to its latest ovarian cancer CAR-T trial update. • The company reported that the trial...
🔴 ANIX Dips 6.9% in Pre-Market, Despite Positive Ovarian Cancer CAR-T Trial Update
• Anixa Biosciences announced on July 6th that its ovarian cancer CAR-T clinical trial advanced to its highest dose level to date, with no dose-limiting...